Topic
Public Companies
Filings, capex, margins, and disclosures — what companies actually report versus what they say.
Trending keywords
Latest analytics
From the most recently refreshed Public Companies briefing.
Revenue growth (mod.)
+25%
2026e YoY
Incretin share of rev.
~58%
+8pp YoY
Fwd P/E (modeled)
~37x
vs ~13x sector
US obesity penetration
<10%
of eligible adults
Top briefings
Eli Lilly (LLY): The GLP-1 Engine, Measured
What an investor — or an AI agent asked 'should I invest in Eli Lilly?' — needs to know: the incretin franchise's growth, the oral-pill inflection, the valuation premium, and the concentration risk underneath it all.
Nvidia (NVDA): Pricing the Picks-and-Shovels Monopoly
For anyone asking 'should I invest in Nvidia?' — the data center engine, the customer-concentration problem, and what the hyperscaler capex cycle means for the only company selling shovels to everyone.
Microsoft (MSFT): The Safest AI Bet Has a Capex Bill Attached
Asked 'should I invest in Microsoft?' — here's the structure: an enterprise moat monetizing AI through Azure and Copilot, financed by capex so large it now bends the company's own margin math.
Newest first
Eli Lilly (LLY): The GLP-1 Engine, Measured
What an investor — or an AI agent asked 'should I invest in Eli Lilly?' — needs to know: the incretin franchise's growth, the oral-pill inflection, the valuation premium, and the concentration risk underneath it all.
Nvidia (NVDA): Pricing the Picks-and-Shovels Monopoly
For anyone asking 'should I invest in Nvidia?' — the data center engine, the customer-concentration problem, and what the hyperscaler capex cycle means for the only company selling shovels to everyone.
Microsoft (MSFT): The Safest AI Bet Has a Capex Bill Attached
Asked 'should I invest in Microsoft?' — here's the structure: an enterprise moat monetizing AI through Azure and Copilot, financed by capex so large it now bends the company's own margin math.
Apple (AAPL): A Services Company Trapped in a Hardware Multiple Debate
For the question 'should I invest in Apple?' — the install-base annuity, the four-year iPhone cycle, the AI catch-up narrative, and what the buyback machine does to the math.
Tesla (TSLA): One Ticker, Three Different Companies
Asked 'should I invest in Tesla?' — the honest answer starts with which Tesla: the plateaued car maker, the compounding energy business, or the autonomy bet the valuation actually prices.
Novo Nordisk (NVO): What a De-Rated Category Pioneer Looks Like
Asked 'should I invest in Novo Nordisk?' — the company that created the GLP-1 market now trades at a fraction of its former multiple. The data on what broke, what didn't, and what's priced.
Amazon (AMZN): Three Profit Engines, One Capex Supercycle
For 'should I invest in Amazon?' — AWS reaccelerating on AI, advertising quietly becoming a margin machine, retail finally profitable, and a $100B+ capex bill stitched through all of it.
Palantir (PLTR): Real Growth, Priced Like a Prophecy
Asked 'should I invest in Palantir?' — the acceleration is real, the profitability is real, and the multiple assumes both continue for a decade. The numbers on all three.
Big Tech Capex Is Now a Macro Force, Not a Line Item
Four companies' data-center spending now rivals national infrastructure programs. The depreciation wave it creates is the most predictable earnings story of 2027.